PRACA PRZEGLĄDOWA
The problem of residual pain in the assessment of rheumatoid arthritis activity
1
Medical University of Warsaw, Poland
2
Rheumatology Student Research Group at the National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
3
Early Arthritis Clinic, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland
Data nadesłania: 19-04-2024
Data ostatniej rewizji: 02-06-2024
Data akceptacji: 07-06-2024
Data publikacji: 12-07-2024
Autor do korespondencji
Reumatologia 2024;62(3):176-186
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Residual pain is a major unmet medical need observed in patients suffering from rheumatoid arthritis (RA), which decreases their quality of life, even after achieving remission or low disease activity. The article has two aims: 1) to present mechanisms involved in the pathophysiology of residual pain, both inflammatory and non-inflammatory, i.e. neuropathic and nociplastic pain, as well as secondary pain syndromes, i.e. osteoarthritis and fibromyalgia, which can contribute to residual pain; 2) to show the limitations of current disease activity measures recommended by European Alliance of Associations for Rheumatology (EULAR) and American College of Rheumatology (ACR), which raise the need for a separate assessment of pain, and examples of methods that could be used by medical professionals to assess the pain and make a differential diagnosis. In conclusion, establishing a valid method to assess pain is essential to identify the pathomechanism of residual pain and to create treatments tailored specifically to individual RA patients.
REFERENCJE (92)
1.
National Institute of Arthritis and Musculoskeletal and Skin Diseases. Rheumatoid Arthritis: Diagnosis, Treatment, and Steps to Take. Available at: https://www.niams.nih.gov/heal... (Access: 31.12.2023).
2.
Lee YC, Frits ML, Iannaccone CK, et al. Subgrouping of patients with rheumatoid arthritis based on pain, fatigue, inflammation, and psychosocial factors. Arthritis Rheumatol 2014; 66: 2006–2014, DOI: 10.1002/art.38682.
3.
Lee YC, Cui J, Lu B, et al. Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 2011; 13: R83, DOI: 10.1186/ar3353.
4.
McWilliams DF, Walsh DA. Factors predicting pain and early discontinuation of tumour necrosis factor-alpha-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register. BMC Musculoskelet Disord 2016; 17: 337, DOI: 10.1186/s12891-016-1192-7.
5.
van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34 Suppl 2: 74–78.
6.
Machold KP, Stamm TA, Nell VP, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007; 46: 342–349, DOI: 10.1093/rheumatology/kel237.
7.
IASP Terminology Working Group. Part III: Pain Terms. A Current List with Definitions and Notes on Usage. In: Merskey H, Bogduk N, eds. Classification of Chronic Pain. IASP Press 1994; 209–214.
8.
Yam MF, Loh YC, Tan CS, et al. General pathways of pain sensation and the major neurotransmitters involved in pain regulation. Int J Mol Sci 2018; 19: 2164, DOI: 10.3390/ijms19082164.
9.
Zhang A, Lee YC. Mechanisms for joint pain in rheumatoid arthritis (RA): from cytokines to central sensitization. Curr Osteoporos Rep 2018; 16: 603–610, DOI: 10.1007/s11914-018-0473-5.
10.
Kathryn B, Nidhi S. Understanding the mechanisms of pain in rheumatoid arthritis. In: Rheumatoid Arthritis. Reem Hamdy AM (ed.) IntechOpen; 2020.
11.
Vergne-Salle P, Bertin P. Chronic pain and neuroinflammation. Joint Bone Spine 2021; 88: 105222, DOI: 10.1016/j.jbspin.2021.105222.
12.
Yue JX, Wang RR, Yu J, et al. Histamine upregulates Nav1.8 expression in primary afferent neurons via H2 receptors: involvement in neuropathic pain. CNS Neurosci Ther 2014; 20: 883–892, DOI: 10.1111/cns.12305.
13.
Parada CA, Tambeli CH, Cunha FQ, Ferreira SH. The major role of peripheral release of histamine and 5-hydroxytryptamine in formalin-induced nociception. Neuroscience 2001; 102: 937–944, DOI: 10.1016/s0306-4522(00)00523-6.
14.
Coutaux A, Adam F, Willer JC, Le Bars D. Hyperalgesia and allodynia: peripheral mechanisms. Joint Bone Spine 2005; 72: 359–371, DOI: 10.1016/j.jbspin.2004.01.010.
15.
DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem 2016; 139 Suppl 2 (Suppl 2): 136–153, DOI: 10.1111/jnc.13607.
16.
Suss P, Rothe T, Hoffmann A, et al. The joint-brain axis: insights from rheumatoid arthritis on the crosstalk between chronic peripheral inflammation and the brain. Front Immunol 2020; 11: 612104, DOI: 10.3389/fimmu.2020.612104.
17.
Binshtok AM, Wang H, Zimmermann K, et al. Nociceptors are interleukin-1beta sensors. J Neurosci 2008; 28: 14062–14073, DOI: 10.1523/JNEUROSCI.3795-08.2008.
18.
Malange KF, Navia-Pelaez JM, Dias EV, et al. Macrophages and glial cells: innate immune drivers of inflammatory arthritic pain perception from peripheral joints to the central nervous system. Front Pain Res (Lausanne) 2022; 3: 1018800, DOI: 10.3389/fpain.2022.1018800.
19.
Sebba A. Pain: a review of interleukin-6 and its roles in the pain of rheumatoid arthritis. Open Access Rheumatol 2021; 13: 31–43, DOI: 10.2147/OARRR.S291388.
20.
Mahmoud S, Gharagozloo M, Simard C, Gris D. Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release. Cells 2019; 8: 184, DOI: 10.3390/cells8020184.
21.
Li T, Chen X, Zhang C, et al. An update on reactive astrocytes in chronic pain. J Neuroinflammation 2019; 16: 140, DOI: 10.1186/s12974-019-1524-2.
22.
McWilliams DF, Rahman S, James RJE, et al. Disease activity flares and pain flares in an early rheumatoid arthritis inception cohort; characteristics, antecedents and sequelae. BMC Rheumatol 2019; 3: 49, DOI: 10.1186/s41927-019-0100-9.
23.
Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009; 10: 895–926, DOI: 10.1016/j.jpain.2009.06.012.
24.
Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell 2009; 139: 267–284, DOI: 10.1016/j.cell.2009.09.028.
25.
Choy E, Bykerk V, Lee YC, et al. Disproportionate articular pain is a frequent phenomenon in rheumatoid arthritis and responds to treatment with sarilumab. Rheumatology (Oxford) 2023; 62: 2386–2393, DOI: 10.1093/rheumatology/keac659.
26.
Ahmed L, Biddle K, Blundell A, et al. POS0179 Pain characteristics in people with active rheumatoid arthritis receiving adalimumab and abatacept: a feasibility trial of nociceptive, neuropathic and pain sensitisation components. Ann Rheum Dis 2023; 82 (Suppl 1): 314–314, DOI: 10.1136/annrheumdis-2023-eular.1955.
27.
Fautrel B, Kirkham B, Pope JE, et al. Effect of Baricitinib And Adalimumab In Reducing Pain And Improving Function In Patients With Rheumatoid Arthritis In Low Disease Activity: Exploratory Analyses From RA-BEAM. J Clin Med 2019; 8: 1394, DOI: 10.3390/jcm8091394.
28.
Dougados M, Taylor PC, Bingham CO 3rd, et al. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open 2022; 8: e002478, DOI: 10.1136/rmdopen-2022-002478.
29.
Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 2019; 71: 1788–1800, DOI: 10.1002/art.41032.
30.
Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017; 376: 652–662, DOI: 10.1056/NEJMoa1608345.
31.
Becede M, Alasti F, Gessl I, et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum 2019; 49: 211–217, DOI: 10.1016/j.semarthrit.2019.02.004.
32.
Wiesenfeld-Hallin Z. Sex differences in pain perception. Gend Med 2005; 2: 137–145, DOI: 10.1016/s1550-8579 (05)80042-7.
33.
Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 446–451, DOI: 10.1016/s0002-9343 (01)00872-5.
34.
Nell VP, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43: 906–914, DOI: 10.1093/rheumatology/keh199.
35.
Saevarsdottir S, Wallin H, Seddighzadeh M, et al. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Ann Rheum Dis 2011; 70: 469–475, DOI: 10.1136/ard.2010.139212.
36.
Bingham CO 3rd, Pohl C, Woodworth TG, et al. Developing a standardized definition for disease “flare” in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 2009; 36: 2335–2341, DOI: 10.3899/jrheum.090369.
37.
Hewlett S, Sanderson T, May J, et al. ‘I’m hurting, I want to kill myself’: rheumatoid arthritis flare is more than a high joint count – an international patient perspective on flare where medical help is sought. Rheumatology (Oxford) 2012; 51: 69–76, DOI: 10.1093/rheumatology/keq455.
38.
Bartlett SJ, Hewlett S, Bingham CO 3rd, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 2012; 71: 1855–1860, DOI: 10.1136/annrheumdis-2011-201201.
39.
Koop SM, ten Klooster PM, Vonkeman HE, et al. Neuropathic-like pain features and cross-sectional associations in rheumatoid arthritis. Arthritis Res Ther 2015; 17: 237, DOI: 10.1186/s13075-015-0761-8.
40.
Ahmed S, Magan T, Vargas M, et al. Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting. J Pain Res 2014; 7: 579–588, DOI: 10.2147/JPR.S69011.
41.
Perrot S, Dieude P, Perocheau D, Allanore Y. Comparison of pain, pain burden, coping strategies, and attitudes between patients with systemic sclerosis and patients with rheumatoid arthritis: a cross-sectional study. Pain Med 2013; 14: 1776–1785, DOI: 10.1111/pme.12213.
42.
Hallstrom H, Norrbrink C. Screening tools for neuropathic pain: can they be of use in individuals with spinal cord injury? Pain 2011; 152: 772–779, DOI: 10.1016/j.pain.2010.11.019.
43.
Kosek E, Cohen M, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain 2016; 157: 1382–1386, DOI: 10.1097/j.pain.0000000000000507.
44.
Murphy AE, Minhas D, Clauw DJ, Lee YC. Identifying and managing nociplastic pain in individuals with rheumatic diseases: a narrative review. Arthritis Care Res (Hoboken) 2023; 75: 2215–2222, DOI: 10.1002/acr.25104.
45.
Guimaraes M, Pinto M, Resende GG, et al. Discordance between the patient’s and physician’s global assessment in rheumatoid arthritis: Data from the REAL study – Brazil. PLoS One 2020; 15: e0230317, DOI: 10.1371/journal.pone.0230317.
46.
Zeman MN, Scott PJ. Current imaging strategies in rheumatoid arthritis. Am J Nucl Med Mol Imaging 2012; 2: 174–220.
47.
England BR, Tiong BK, Bergman MJ, et al. 2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res (Hoboken) 2019; 71: 1540–1555, DOI: 10.1002/acr.24042.
48.
Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23 (5 Suppl 39): S93–S99.
49.
Kang JH, Choi SE, Park DJ, Lee SS. Disentangling diagnosis and management of fibromyalgia. J Rheum Dis 2022; 29: 4–13, DOI: 10.4078/jrd.2022.29.1.4.
50.
Goubert D, Danneels L, Graven-Nielsen T, et al. Differences in pain processing between patients with chronic low back pain, recurrent low back pain, and fibromyalgia. Pain Physician 2017; 20: 307–318.
51.
Staud R, Koo E, Robinson ME, Price DD. Spatial summation of mechanically evoked muscle pain and painful aftersensations in normal subjects and fibromyalgia patients. Pain 2007; 130: 177–187, DOI: 10.1016/j.pain.2007.03.015.
52.
de la Coba P, Bruehl S, Moreno-Padilla M, Reyes Del Paso GA. Responses to slowly repeated evoked pain stimuli in fibromyalgia patients: evidence of enhanced pain sensitization. Pain Med 2017; 18: 1778–1786, DOI: 10.1093/pm/pnw361.
53.
de la Coba P, Bruehl S, Galvez-Sanchez CM, Reyes Del Paso GA. Slowly repeated evoked pain as a marker of central sensitization in fibromyalgia: diagnostic accuracy and reliability in comparison with temporal summation of pain. Psychosom Med 2018; 80: 573–580, DOI: 10.1097/PSY.0000000000000599.
54.
Bhargava J, Hurley JA. Fibromyalgia. StatPearls Publishing, Treasure Island (FL) 2024.
55.
Jones GT, Atzeni F, Beasley M, et al. The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. Arthritis Rheumatol 2015; 67: 568–575, DOI: 10.1002/art.38905.
56.
Duffield SJ, Miller N, Zhao S, Goodson NJ. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2018; 57: 1453–1460, DOI: 10.1093/rheumatology/key112.
57.
Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017; 76: 318–328, DOI: 10.1136/annrheumdis-.
59.
Duran J, Combe B, Niu J, et al. The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort. Rheumatology (Oxford) 2015; 54: 2166–2170, DOI: 10.1093/rheumatology/kev254.
60.
Salaffi F, Gerardi MC, Atzeni F, et al. The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. Rheumatol Int 2017; 37: 2035–2042, DOI: 10.1007/s00296-017-3792-4.
61.
Durmaz Y, Ilhanli I. Rheumatoid arthritis activity scores in patients with and without fibromyalgia syndrome. Ann Saudi Med 2021; 41: 246–252, DOI: 10.5144/0256-4947.2021.246.
62.
Mohammed A, Alshamarri T, Adeyeye T, et al. A comparison of risk factors for osteo- and rheumatoid arthritis using NHANES data. Prev Med Rep 2020; 20: 101242, DOI: 10.1016/j.pmedr.020.101242.
63.
Mathias K, Amarnani A, Pal N, et al. Chronic pain in patients with rheumatoid arthritis. Curr Pain Headache Rep 2021; 25: 59, DOI: 10.1007/s11916-021-00973-0.
64.
Ruiz-Medrano E, Espinosa-Ortega HF, Arce-Salinas CA. The effect of concomitant hand osteoarthritis on pain and disease activity in patients with rheumatoid arthritis. Clin Rheumatol 2019; 38: 2709–2716, DOI: 10.1007/s10067-019-04574-6.
65.
Inoue K, Shichikawa K, Nishioka J, Hirota S. Older age onset rheumatoid arthritis with or without osteoarthritis. Ann Rheum Dis 1987; 46: 908–911, DOI: 10.1136/ard.46.12.908.
66.
Beswick AD, Wylde V, Gooberman-Hill R, et al. What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients. BMJ Open 2012; 2: e000435, DOI: 10.1136/bmjopen-2011-000435.
67.
Wylde V, Sayers A, Odutola A, et al. Central sensitization as a determinant of patients’ benefit from total hip and knee replacement. Eur J Pain 2017; 21: 357–365, DOI: 10.1002/ejp.929.
68.
Benjamin O, Goyal A, Lappin SL. Disease-Modifying Antirheumatic Drugs (DMARD). StatPearls Publishing, Treasure Island (FL) 2024.
69.
Joseph D, Tintinger GR, Ker JA, Pannell N. Adverse effects of biologic anti-inflammatory agents on the respiratory system: A review. Afr J Thorac Crit Care Med 2021; 27: 10.7196/AJTCCM.2021.v27i2.11, DOI: 10.7196/AJTCCM.2021.v27i2.117.
70.
Perrot S, Bouhassira D, Fermanian J; CEDR (Cercle d’Etude de la Douleur en Rhumatologie). Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Pain 2010; 150: 250–256, DOI: 10.1016/j.pain.2010.03.034.
71.
Ferraz MB, Quaresma MR, Aquino LR, et al. Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol 1990; 17: 1022–1024.
72.
Renskers L, van Uden R, Huis AMP, et al. Comparison of the construct validity and reproducibility of four different types of patient-reported outcome measures (PROMs) in patients with rheumatoid arthritis. Clin Rheumatol 2018; 37: 3191–3199, DOI: 10.1007/s10067-018-4285-x.
73.
Mucke M, Cuhls H, Radbruch L, et al. Quantitative sensory testing (QST). English version. Schmerz 2021; 35 (Suppl 3): 153–160, DOI: 10.1007/s00482-015-0093-2.
74.
Horowitz SH. Chapter 3. Neuropathic pain: is the emperor wearing clothes? In: Smith HS (ed.). Current Therapy in Pain. W.B. Saunders 2009: 9–14.
75.
Park G, Kim CW, Park SB, et al. Reliability and usefulness of the pressure pain threshold measurement in patients with myofascial pain. Ann Rehabil Med 2011; 35: 412–417, DOI: 10.5535/arm.2011.35.3.412.
76.
McDougall C, Wiens D, Smolik I, et al. Beyond the visual analog scale: results from a multimodal pain assessment pilot study in first-degree relatives of patients with rheumatoid arthritis. ACR Open Rheumatol 2022; 4: 1027–1029, DOI: 10.1002/acr2.11497.
77.
Bhattacharyya A, Hopkinson LD, Nolet PS, Srbely J. The reliability of pressure pain threshold in individuals with low back or neck pain: a systematic review. Br J Pain 2023; 17: 579–591, DOI: 10.1177/20494637231196647.
78.
Stausholm MB, Bjordal JM, Moe-Nilssen R, Naterstad IF. Pain pressure threshold algometry in knee osteoarthritis: intra- and inter-rater reliability. Physiother Theory Pract 2023; 39: 615–622, DOI: 10.1080/09593985.2021.2023929.
79.
Singh H, Arora S, Tanwar V, et al. The Validity and Sensitivity of Rheumatoid Arthritis Pain Scale on a Different Ethnic Group From Indian Rheumatoid Arthritis Patients. Arch Rheumatol 2020; 35: 90–96, DOI: 10.5606/ArchRheumatol.2020.7348.
80.
Anderson DL. Development of an instrument to measure pain in rheumatoid arthritis: Rheumatoid Arthritis Pain Scale (RAPS). Arthritis Rheum 2001; 45: 317–323, DOI: 10.1002/1529-0131(200108)45:4<317::AID-ART343>3.0.CO;2-X.
81.
Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006; 22: 1911–1920, DOI: 10.1185/030079906X132488.
82.
Truini A, Aleksovska K, Anderson CC, et al. Joint European Academy of Neurology – European Pain Federation – Neuropathic Pain Special Interest Group of the International Association for the Study of Pain guidelines on neuropathic pain assessment. Eur J Neurol 2023; 30: 2177–2196, DOI: https://doi.org/10.1111/ene.15....
83.
Timmerman H, Steegers MAH, Huygen F, et al. Investigating the validity of the DN4 in a consecutive population of patients with chronic pain. PLoS One 2017; 12: e0187961, DOI: 10.1371/journal.pone.0187961.
84.
Parekh K, Taylor WJ. The patient activity scale-II is a generic indicator of active disease in patients with rheumatic disorders. J Rheumatol 2010; 37: 1932–1934, DOI: 10.3899/jrheum.100008.
85.
Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am 2009; 35: 773–778, DOI: 10.1016/j.rdc.2009.10.008.
86.
Suzuki M, Takahashi N, Sobue Y, et al. AB0238 Usefulness of RAPID3 in assessing unmet needs of rheumatoid arthritis patients from the T-FLAG study. Ann Rheum Dis 2023; 82 (Suppl 1): 1303–1304, DOI: 10.1136/annrheumdis-2023-eular.2604.
87.
Bardwell WA, Nicassio PM, Weisman MH, et al. Rheumatoid Arthritis Severity Scale: a brief, physician-completed scale not confounded by patient self-report of psychological functioning. Rheumatology 2002; 41: 38–45, DOI: 10.1093/rheumatology/41.1.38.
88.
Neblett R, Cohen H, Choi Y, et al. The Central Sensitization Inventory (CSI): establishing clinically significant values for identifying central sensitivity syndromes in an outpatient chronic pain sample. J Pain 2013; 14: 438–445, DOI: 10.1016/j.jpain.2012.11.012.
89.
Cuesta-Vargas AI, Neblett R, Chiarotto A, et al. Dimensionality and reliability of the central sensitization inventory in a pooled multicountry sample. J Pain 2018; 19: 317–329, DOI: 10.1016/j.jpain.2017.11.006.
90.
den Boer C, Terluin B, van der Wouden JC, et al. Tests for central sensitization in general practice: a Delphi study. BMC Fam Pract 2021; 22: 206, DOI: 10.1186/s12875-021-01539-0.
91.
Biddle K, Sofat N. Understanding the mechanisms of pain in rheumatoid arthritis. rheumatoid arthritis – other perspectives towards a better practice. IntechOpen 2020, DOI: https://doi.org/10.5772/intech....
92.
Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol 2021; 17: 17–33, DOI: 10.1038/s41584-020-00541-7.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
ARTYKUŁ POWIĄZANY
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
Przetwarzamy dane osobowe zbierane podczas odwiedzania serwisu. Realizacja funkcji pozyskiwania informacji o użytkownikach i ich zachowaniu odbywa się poprzez dobrowolnie wprowadzone w formularzach informacje oraz zapisywanie w urządzeniach końcowych plików cookies (tzw. ciasteczka). Dane, w tym pliki cookies, wykorzystywane są w celu realizacji usług, zapewnienia wygodnego korzystania ze strony oraz w celu monitorowania ruchu zgodnie z Polityką prywatności. Dane są także zbierane i przetwarzane przez narzędzie Google Analytics (więcej).
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
Możesz zmienić ustawienia cookies w swojej przeglądarce. Ograniczenie stosowania plików cookies w konfiguracji przeglądarki może wpłynąć na niektóre funkcjonalności dostępne na stronie.
